SUS	SPECT ADVERS	E REACTION	ON REPO	RT																
	DI LOT ADVERO	LINEAGIN	JIVINEI O	IVI							_				_				_	
2025-12421(1)																				
				L DEAC	TION II	NEOD	NAATIONI		<u> </u>					<u> </u>	<u> </u>				ı	
1. PATIENT INITIALS	I. REACTION INFORMATION 1. PATIENT INITIALS 1a. COUNTRY											ΕT			8-12	CHE	CK /	ALL		
(first, last)	GUATEMALA	Day	Month	Year	Years 51		Female	Da	/	Month		Year			İ	TO A	DVI	PRIATI ERSE	Ξ	
L-S	CO/ (TEIWI/ CE/ (19	May 1973		31	Cinaic			Apr		2025				REACTION					
	7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)														İ	PATIE	ENT	DIED		
1) Lack of effect of the product when applied to the forehead (Lack of drug effect (10023610), Drug ineffective (10013709)) (/Apr/2025 -) - Not applicable														9))	LIFE THREATENING					
2) Dysport applied to the forehead (Off label use in unapproved indication (10084345), Off label use (10053762))																INVO		D OR GED IN	ΡΔΤΙ	FNT
(09/Apr/2025 -) - Not applicable																	PITA	LIZATIO		
															PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY					
															CONGENITAL ANOMALY					
															OTHER MEDICALLY IMPORTANT CONDITION					
				I. SUSPECT	DRUG	S(S)IN	FORMAT	ION												
14. SUSPECT DRUG(,,	,													20.	DID E				
1) DYSPORT (BOTULINUM TOXIN TYPE A, BOTULINUM TOXIN TYPE A) (Suspect) (Powder for solution for injection) (004458) Cont.													nt	ABATE AFTER STOPPING DRUG? YES NO NA						
15. DAILY DOSE(S)							16. ROUTE(S) OF ADMINISTRATION 21. DID EVENT													
1) (165 international unit(s), in 1 Cyclical)							1) Unknown REAPPEAR AFTER REINTRODUCTION											N		
																YES		NO	L	□ _{NA}
17. INDICATION(S) FO															(N	A : No	ot A	pplica	able)
18. THERAPY DATE(S) (from/to) 19. THERAPY DURATION																				
1) (09/Apr/2025 - 09/Apr/2025) 1) 1 Days																				
Γ				CONCOMITA		,	,		′											
22. CONCOMITANT D No concomitants us		ES OF ADM	IINISTRATI	ON (exclude the	nose us	ed to tr	eat reactior	ר)												
	•																			
23. OTHER RELEVAN	IT HISTORY (e.g. o	diagnostics,	allergies, pi	egnancy with I	ast mor	nth of p	eriod, etc.)													
•				IV. MANUFA	CTUR	ER INI	FORMATI	ION												
24a. NAME AND ADD																				
Name : IPSEN Grou 70 Rue Balard	•	a Developn	nent																	
Paris, 75015, FRAN 24.REPORT NULLIFIE																				
24b. MFR CONTROL NO.																				
2025-12421(1)																				
	BY MANUFACTURER																			
29/May/2025																				
DATE OF THIS REPORT 25a. REPORT TYPE																				
12/Jun/2025																				

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description:

The initial version of this non-serious spontaneous non-AE case was reported by physician in Guatemala on 22-May-2025 and transmitted to our licensee partner Biopas (Reference number- 2025-GT-000004) and then transmitted to Ipsen GPS ICSR vendor (via mailbox) on 23-May-2025.

It concerns a 51-year-old adult female patient, who received Dysport (Botulinum toxin type A) for forehead (Off label use in unapproved indication) and experienced Lack of effect of the product when applied to the forehead (lack of drug effect). The patient height and weight were not reported.

No past disease, underlying condition, or concomitant medications were reported, the patient had previously administered the Dysport product on 03-Sep-2024 and had the expected paralysis effect, but did not report dose, route, number of therapies, site of administration.

On 09-Apr-2025, patient started treatment with single cyclical therapy with Dysport, at 165 u dose, powder for solution for injection via unknown route for forehead (Off label use in unapproved indication). The batch number was 004458 and expiration date were not reported.

On unknown date in Apr-2025, at the time of routine review 21 days later it was found that the product has had no effect.

Action taken and de challenge with Dysport in response to the events were not applicable.

At the time of this report, outcome of the events were not applicable.

The reporter did not provide the causality assessment for the events. However, as per data handling guidance, reporter causality coded as no reasonable possibility for non-AE case.

SERIOUSNESS AS PER REPORTER: Not serious (Lack of effect of the product when applied to the forehead, Dysport applied to the forehead) SERIOUSNESS AS PER COMPANY: Not serious (Lack of effect of the product when applied to the forehead, Dysport applied to the forehead) CAUSALITY AS PER REPORTER: No reasonable possibility (Lack of effect of the product when applied to the forehead, Dysport applied to the forehead)

CAUSALITY AS PER COMPANY: No reasonable possibility (Lack of effect of the product when applied to the forehead, Dysport applied to the forehead)

EXPECTEDNESS: Unlabelled (Lack of effect of the product when applied to the forehead, Dysport applied to the forehead)

No further information was available.

Follow-up information was received from physician on 29-May-2025 via our licensee partner Biopas (Reference number: 2025-GT-000004) and then transmitted to Ipsen GPS ICSR vendor (via mailbox) on 30-May-2025.

In this follow up, information was provided about patient's details which had already been reported. Hence, this information was regarded as non-significant.

Company Remarks (Sender's Comments):

Events off label use, drug ineffective are special situation for which causality cannot be assessed. Considering above mentioned, according to the WHO-UMC method of assessment, the causal relationship between the events and the suspect drug is assessed as unassessable by Ipsen.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

Therapy Dates

1) Drug : DYSPORT (BOTULINUM TOXIN TYPE A)

Active Substance : BOTULINUM TOXIN TYPE A

Drug Characterization : Suspect

Form of Admin : Powder for solution for injection

Lot Number : 004458

Daily Dose : (165 international unit(s), in 1 Cyclical)

Route of Admin : Unknown

Indications : 1) forehead [10048042 - Wrinkles]

2) off label use [10053762 - Off label use] : From : 09/Apr/2025 To :09/Apr/2025

Therapy Duration : 1 Days

Action(s) Taken With Drug : Not applicable

Causality

1) Lack of effect of the product when applied to the forehead (Lack of drug effect - 10023610, Drug ineffective - 10013709)

Causality as per reporter : No reasonable possibility

Mfr. CONTROL NO :2025-12421(1)

Continuation Sheet for CIOMS report

Causality as per Mfr : No reasonable possibility

DeChallenge : Not applicable

2) Dysport applied to the forehead (Off label use in unapproved indication - 10084345, Off label use - 10053762)

Causality as per reporter : No reasonable possibility
Causality as per Mfr : No reasonable possibility

DeChallenge : Not applicable

Labeling:

Lack of effect of the product when applied to the forehead CORE
 UnLabeled

2) Dysport applied to the forehead

CORE UnLabeled